IDEXX Laboratories, Inc. $IDXX Shares Sold by SYM FINANCIAL Corp

SYM FINANCIAL Corp cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 52.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 877 shares of the company’s stock after selling 967 shares during the quarter. SYM FINANCIAL Corp’s holdings in IDEXX Laboratories were worth $560,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. WealthCollab LLC acquired a new stake in IDEXX Laboratories in the second quarter worth $30,000. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the third quarter valued at $31,000. Armstrong Advisory Group Inc. grew its position in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after acquiring an additional 19 shares during the last quarter. Salomon & Ludwin LLC bought a new position in shares of IDEXX Laboratories during the third quarter worth about $35,000. Finally, Ameritas Advisory Services LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $36,000. Institutional investors own 87.84% of the company’s stock.

Insider Activity

In related news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.98% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have commented on IDXX. UBS Group upped their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Barclays assumed coverage on IDEXX Laboratories in a research report on Monday, December 8th. They set an “overweight” rating and a $850.00 price objective for the company. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Finally, Morgan Stanley increased their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $763.50.

IDEXX Laboratories Stock Down 1.6%

Shares of IDXX stock opened at $676.71 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. The business’s fifty day moving average is $706.46 and its 200-day moving average is $658.91. The stock has a market cap of $54.04 billion, a PE ratio of 53.66, a price-to-earnings-growth ratio of 3.67 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.08. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The company’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.